Jason S Lipetz – Trademark Portfolio

Entity Type: 01

Jason S Lipetz holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 5 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include 11, GLOVE IT, SPINE - 1 - 1, and TAKE THIS PHONE AND GLOVE IT. The owner is based in Roslyn, NY.

90 Ash Drive

Roslyn, NY 11576

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Jason S Lipetz's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (5 filings)

Advertising; business management; business administration; office functions

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does Jason S Lipetz have?

Jason S Lipetz has 6 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 abandoned.

What trademark classes does Jason S Lipetz file in?

Jason S Lipetz files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 44 (Medical Services). Class 35 covers advertising; business management; business administration; office functions.

What are Jason S Lipetz's most well-known trademarks?

Jason S Lipetz's registered trademark portfolio includes well-known marks such as 11, GLOVE IT, SPINE - 1 - 1, and TAKE THIS PHONE AND GLOVE IT. These are among 5 currently registered trademarks in the portfolio.

What is Jason S Lipetz's trademark registration success rate?

Jason S Lipetz has a 83% trademark registration rate, with 5 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.